
MOLECULAR ANALYSIS OF RING Y CHROMOSOME
IN A 10-YEAR-OLD BOY WITH MIXED GONADAL
DYSGENESIS AND GROWTH HORMONE DEFICIENCY Milenkovic T1,*, Guc-Scekic M2, Zdravkovic D1,3, Topic V4,
Liehr T5, Joksic G6, Radivojevic D2, Lakic N2 *Corresponding Author: Tatjana Milenkovic, Department of Endocrinology, Institute for Mother and Child
Healthcare of Serbia “Dr. Vukan Cupic,” Radoja Dakica 6-8, 11 070 Belgrade, Serbia; Tel.: +381-11-3018-109;
Fax: +381-11-3108-257; E-mail: tanjamil@eunet.rs page: 71
|
MATERIALS AND METHODS
Clinical Report. A 10-year-old boy of healthy
and unrelated parents was referred for evaluation of
perineal hypospadias and unilateral cryptorchidism,
anomalies that were incompletely surgically corrected in early childhood in a regional hospital. He was the
second child in the family, born at term after a normal
pregnancy and delivery: birth weight was 2850 g and
length 49 cm. His motor and mental development was
normal. He was obese from early childhood. On admission
to our hospital, his height was 129.3 cm (3rd-
10th centile), but inconsistent for the target height of
173.5 cm (25th-50th centile). His weight was 53.6
kg, body mass index (BMI) was 32.99 kg/m2 (>97th
centile) and he had significant acanthosis nigricans on
the neck, in the axillae and the cubital area. Bilateral
pseudogynecomastia was also noticed. His external
genitalia appeared predominantly male, his penis was
4.5 cm, and showed scars from previous operations.
The large scrotal sac contained a 4 ml testis on the left,
and an irregular mass of 0.5 ml on the right.
Basal gonadotrophin levels were: luteinizing hormone
(LH) 0.1 IU/L (0.03-0.43 IU/L), follicle-stimulating
hormone (FSH) 1.7 IU/L (0.22-1.92 IU/L) and testosterone
0.1 nmol/L (0.06-0.8 nmol/L). Testosterone
response to a short human chorionic gonadotrophine
(HCG) test showed 1.2 and 2.6 nmol/L on days 3 and 4,
respectively. Peak value of GH in the clonidine test was
1.2 mIU/Ll (>20 mIU/L), while values during overnight
profile of GH were as follows: for peak value 1.1 mIU/L
(>13.1 mIU/L) and for mean value 0.23 mIU/L (>3.2
mIU/L). The level of insulin-like growth factor-1 (IGF-
1) was 164 ng/mL (88-452 ng/mL) and IGF binding
protein-3 (IGFBP-3) was 4.9 μg/mL (2.1-7.7 μg/mL).
Serum free thyroxine and thyroid-stimulating hormone
were normal. An oral glucose tolerance test showed
no glucose intolerance but the insulin levels peaked at
656.8 mIU/L (100 mIUL/L). The homeostasis model
assessment of insulin resistance (HOMA-IR) was 6.6
(3.16). Levels of high density lipoprotein cholesterol
(HDL-c), low-density lipoprotein cholesterorl (LDL-c)
and triglycerides were normal. Bone age was estimated
at 12 years. Magnetic resonance imaging (MRI) of the
brain did not reveal any structural abnormality in the
hypothalamic-pituitary region. Histopathology of surgical
biopsy of the left gonad confirmed the presence
of normal testicular tissue with early spermatogenesis.
The irregular mass from the right side of the scrotal sac
was histopathologically described as a streak gonad
with the presence of a Fallopian tube and rudimentary
uterus. Growth hormone therapy, 1.0 mg/m2/day, was
started. During the first year of treatment his height increased
by 11.0 cm and reached the 25th centile. He
remained extremely obese.
Cytogenetic and Molecular Cytogenetic Studies.
Cytogenetic analysis was performed on G-banded
metaphase chromosomes obtained from cultures of
PHA-stimulated blood lymphocytes from the proband
and his parents according to standard procedures
[14,15]. Fluorescence in situ hybridization (FISH) was
performed on peripheral blood lymphocytes using a Y
chromosome cen satellite probe (Q-Biogene, Carlsbad,
CA, USA) to detect and enumerate the Y chromosomespecific
DYZ3 locus, according to the manufacturer’s
recommendations, using an Axioskop microscope and
MC 80 camera (Carl Zeiss, Jena, Germany). Subcentromere-
specific multicolor FISH (subcenM-FISH)
was performed using RP11-115H13, RP11.71M14 and
a centromeric probe for the Y chromosome, as reported
previously [16]. Fluorescent in situ hybridization with
a subtelomeric TELVysion Xp/Yp probe, spectrum
green (Abbott Laboratories, Abbott Park, IL, USA)
and CEPY (DYZ1) probe for Yq12 (Abbott Laboratories)
were used for precise characterization of the ring
Y chromosome. The FISH images were captured on a
Zeiss Axioplan microscope (Zeiss) with the IKAROS
and ISIS digital FISH imaging system (MetaSystems,
Altlussheim, Germany). Telomeric FISH (Telo-FISH)
was performed as described in [17], using the Cy-3 labeled
telomeric PNA probe (CCCTAA) 3 and staining
with DAPI-mounting medium (Vector Laboratories).
Chromosomal analysis was performed using a Zeiss-
Axioimager A1 microscope equipped with a CCD camera
and Axiocam image acquisition software (Imaging
Associate) and software, Image J. Fifteen metaphases
were analyzed for the presence of telomeric signals.
Molecular Genetic Studies. Genomic DNA was
extracted from a peripheral blood sample by standard
procedures [18]. The heterochromatic region of the Y
chromosome was analyzed using polymerase chain reaction
(PCR) with primers flanking part of a Y chromosome-
specific region (the repetitive 3.4 kb sequence
from the DYZ1 family) [19]. Diagnostic testing of Y
chromosome-specific microdeletions was performed
using multiplex PCR amplification directed against
three distinct azoospermia (AZF) regions [AZFa (s84,
s86), AZFb (s127, s134) and AZFc (s254, s255)] on
the long arm of the Y chromosome, the SRY gene on
the short arm of the Y chromosome, and the ZFX/ZFY
gene as an internal control [20]. Positive and negative
controls were provided by DNA samples from a
man with normal spermatogenesis and from a healthy
woman, respectively.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|